ASTRAZENECA DL-,25 SP.ADR
ASTRAZENECA DL-,25 SP.ADR/ US0463531089 /
ZEGA
15/05/2024 08:08:17
|
Var.
-0.50
|
Volume |
Denaro19:47:49 |
Lettera19:47:49 |
Capitalizzazione di mercato |
Dividend Y. |
Rapporto P/E |
71.00EUR
|
-0.70%
|
0 Fatturato: 0.00 |
70.50Quantità in denaro: 360 |
71.00Quantità in lettera: 360 |
220.01 bill.EUR |
- |
- |
Descrizione business
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Consiglio di amministrazione & Consiglio di sorveglianza
CEO |
Pascal Soriot |
Consiglio di amministrazione |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Consiglio di sorveglianza |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Dati aziendali
Name: |
AstraZeneca plc |
Indirizzo: |
1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom |
Telefono: |
0800 783 0033 |
Fax: |
+44-20-7604-8151 |
E-mail: |
Medical.InformationU...eca.com
Medical.InformationUK@astrazeneca.com
|
Internet: |
www.astrazeneca.com |
Industria: |
Healthcare |
Settore: |
Pharmaceutical Industry |
Sub settore: |
Pharmaceuticals |
Fine dell'anno finanziario: |
31/12 |
Flottante libero: |
- |
Data dell'IPO: |
06/04/1999 |
Company calendar
CW 30 | 25/07/2024
Interim Report 2nd Quarter/6 Months
|
CW 32 | 08/08/2024
Ex-Dividend
|
CW 32 | 09/08/2024
Record Date
|
CW 37 | 09/09/2024
Dividend Payment
|
CW 46 | 12/11/2024
Interim Report 3rd Quarter/9 Months
|